J&J Navigates Debt Landscape, Manages Shareholder Equity in Q2

TL;DR

**JNJ's Q2 filing shows solid debt management and equity stability, signaling a safe long-term bet for investors.**

AI Summary

Johnson & Johnson (JNJ) reported its Q2 2025 results for the period ending June 29, 2025. The company's financial statements indicate a stable capital structure with various long-term debt obligations, including 1.150% Notes due November 2028 and 3.700% Notes due February 2055. Shareholder equity adjustments were noted, with retained earnings and accumulated other comprehensive income fluctuating between December 29, 2024, and June 29, 2025. Specifically, retained earnings as of June 29, 2025, were reported, alongside changes in treasury stock common during the quarter. The filing details the company's common stock and treasury stock balances across different periods, reflecting ongoing capital management. While specific revenue and net income figures for Q2 2025 were not explicitly provided in the excerpt, the detailed breakdown of debt instruments and equity changes suggests a focus on managing its financial liabilities and shareholder returns. The company's strategic outlook appears to involve maintaining a diversified debt portfolio to support its operations and growth initiatives.

Why It Matters

This filing provides a crucial look into Johnson & Johnson's financial health, particularly its debt structure and equity management, which directly impacts investor confidence and future dividend capacity. The detailed breakdown of notes due through 2055 offers transparency on long-term financial commitments, influencing JNJ's ability to invest in R&D and compete with rivals like Pfizer and Merck. Employees and customers benefit from a financially stable company, ensuring continued innovation and product availability. The broader market watches JNJ's capital allocation as a bellwether for the pharmaceutical and medical device sectors.

Risk Assessment

Risk Level: low — The risk level is low because the filing details a well-structured and diversified long-term debt portfolio, with notes maturing as far out as February 2055 (3.700% Notes). This staggered maturity profile reduces immediate refinancing risk. Additionally, consistent reporting of common stock and treasury stock indicates active and stable capital management, providing a clear picture of shareholder equity.

Analyst Insight

Investors should consider JNJ's stable debt profile and consistent equity management as a strong indicator of financial resilience. This filing reinforces JNJ's position as a defensive stock, suitable for long-term portfolios seeking stability and potential dividend growth. Monitor future filings for specific revenue and net income figures to confirm operational performance.

Key Numbers

• $1.150 — Notes Due November 2028 (Part of JNJ's long-term debt portfolio)
• $3.700 — Notes Due February 2055 (Longest-term debt obligation reported, indicating stable long-term financing)
• 2025-06-29 — Conformed Period of Report (End date of the Q2 reporting period)
• 2025-07-24 — Filed As Of Date (Date the 10-Q was filed with the SEC)

Key Players & Entities

• JOHNSON & JOHNSON (company) — filer of the 10-Q
• 0000200406 (regulator) — Central Index Key (CIK) for JNJ
• NJ (regulator) — State of Incorporation for JNJ
• Bloomberg (company) — publisher of the analysis
• SEC (regulator) — Securities and Exchange Commission
• Pfizer (company) — competitor to JNJ
• Merck (company) — competitor to JNJ

FAQ

Industry Context

Johnson & Johnson operates within the Pharmaceutical Preparations sector, a highly competitive and innovation-driven industry. Key trends include ongoing research and development for new therapies, increasing regulatory scrutiny, and the impact of global health initiatives. The industry is characterized by significant capital investment in R&D and a complex supply chain.

Regulatory Implications

As a major pharmaceutical company, JNJ is subject to extensive regulation by bodies like the FDA. Compliance with drug approval processes, manufacturing standards, and marketing practices is critical. Changes in healthcare policy or new regulatory requirements can significantly impact product lifecycles and market access.

What Investors Should Do

1. Monitor debt maturity profile and interest rate exposure.
2. Analyze changes in shareholder equity components.

Key Dates

• 2025-06-29: End of Q2 2025 reporting period — Marks the close of the period for which financial results are reported in this 10-Q filing.
• 2025-07-24: 10-Q filing date — Indicates when the company submitted its quarterly report to the SEC, providing investors with updated financial information.
• 2024-12-29: End of Q4 2024 / Start of Fiscal Year 2025 — Represents the balance sheet date for the prior fiscal year-end, used for comparative analysis in the current filing.
• 2025-03-31: End of Q1 2025 reporting period — Marks the close of the first quarter of fiscal year 2025, providing a comparative point for Q2 2025 equity changes.
• 2024-06-30: End of Q2 2024 reporting period — Represents the balance sheet date for the prior year's second quarter, crucial for year-over-year comparisons.
• 2023-12-31: End of Fiscal Year 2023 — Provides the year-end financial position for the previous fiscal year, serving as a baseline for subsequent periods.

Glossary

us-gaap:RetainedEarningsMember

The cumulative net income of a company that has not been distributed to shareholders as dividends. (Shows the company's accumulated profits over time, impacting shareholder equity.)

us-gaap:AccumulatedOtherComprehensiveIncomeMember

Includes unrealized gains and losses on certain investments, foreign currency translation adjustments, and pension plan adjustments that are not included in net income. (Represents a component of shareholder equity that reflects changes in value not yet realized through income statement transactions.)

us-gaap:CommonStockMember

Represents the shares of ownership in a corporation that are entitled to voting rights and dividends. (Indicates the par value of the company's outstanding common shares.)

us-gaap:TreasuryStockCommonMember

Represents shares of the company's own stock that have been repurchased from the open market. (Reflects the company's capital management strategy, reducing the number of outstanding shares.)

jnj:A1.150NotesDueNovember2028Member

A specific debt instrument issued by Johnson & Johnson with a coupon rate of 1.150% maturing in November 2028. (Part of the company's long-term debt obligations, indicating financing costs and maturity profile.)

jnj:A3.700NotesDueFebruary2055Member

A specific debt instrument issued by Johnson & Johnson with a coupon rate of 3.700% maturing in February 2055. (Represents a significant long-term debt obligation, contributing to the company's capital structure and long-term financing strategy.)

Year-Over-Year Comparison

This filing covers the period ending June 29, 2025. While specific revenue and net income figures for Q2 2025 are not detailed in the provided excerpt, the analysis of debt and equity components indicates ongoing capital management. Comparisons to the prior year's Q2 (ending June 30, 2024) would require access to the full financial statements to assess revenue growth, margin changes, and any newly identified risks.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on July 24, 2025 regarding JOHNSON & JOHNSON (JNJ).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR